Logo image of SANA

SANA BIOTECHNOLOGY INC (SANA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SANA - US7995661045 - Common Stock

4.36 USD
-0.14 (-3.11%)
Last: 12/19/2025, 8:15:12 PM
4.43 USD
+0.07 (+1.61%)
After Hours: 12/19/2025, 8:15:12 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SANA. SANA was compared to 530 industry peers in the Biotechnology industry. While SANA seems to be doing ok healthwise, there are quite some concerns on its profitability. SANA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SANA has reported negative net income.
In the past year SANA has reported a negative cash flow from operations.
SANA had negative earnings in each of the past 5 years.
SANA had a negative operating cash flow in each of the past 5 years.
SANA Yearly Net Income VS EBIT VS OCF VS FCFSANA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

SANA's Return On Assets of -53.83% is in line compared to the rest of the industry. SANA outperforms 46.43% of its industry peers.
SANA has a Return On Equity (-120.02%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -53.83%
ROE -120.02%
ROIC N/A
ROA(3y)-45.37%
ROA(5y)-41.34%
ROE(3y)-86.33%
ROE(5y)-74.79%
ROIC(3y)N/A
ROIC(5y)N/A
SANA Yearly ROA, ROE, ROICSANA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

SANA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SANA Yearly Profit, Operating, Gross MarginsSANA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

SANA has more shares outstanding than it did 1 year ago.
SANA has more shares outstanding than it did 5 years ago.
SANA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SANA Yearly Shares OutstandingSANA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
SANA Yearly Total Debt VS Total AssetsSANA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -3.99, we must say that SANA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.99, SANA is in line with its industry, outperforming 41.54% of the companies in the same industry.
There is no outstanding debt for SANA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.99
ROIC/WACCN/A
WACCN/A
SANA Yearly LT Debt VS Equity VS FCFSANA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 4.55 indicates that SANA has no problem at all paying its short term obligations.
SANA has a Current ratio (4.55) which is comparable to the rest of the industry.
A Quick Ratio of 4.55 indicates that SANA has no problem at all paying its short term obligations.
SANA has a Quick ratio (4.55) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.55
Quick Ratio 4.55
SANA Yearly Current Assets VS Current LiabilitesSANA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

1

3. Growth

3.1 Past

SANA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.91%, which is quite impressive.
EPS 1Y (TTM)41.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SANA is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.66% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.66%
EPS Next 2Y22.71%
EPS Next 3Y13.74%
EPS Next 5Y6.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SANA Yearly Revenue VS EstimatesSANA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2032 5M 10M 15M 20M 25M
SANA Yearly EPS VS EstimatesSANA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SANA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SANA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SANA Price Earnings VS Forward Price EarningsSANA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SANA Per share dataSANA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as SANA's earnings are expected to grow with 13.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.71%
EPS Next 3Y13.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SANA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SANA BIOTECHNOLOGY INC

NASDAQ:SANA (12/19/2025, 8:15:12 PM)

After market: 4.43 +0.07 (+1.61%)

4.36

-0.14 (-3.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)03-16 2026-03-16/amc
Inst Owners80.41%
Inst Owner Change11.37%
Ins Owners6.74%
Ins Owner Change0.11%
Market Cap1.16B
Revenue(TTM)N/A
Net Income(TTM)-234.41M
Analysts85.33
Price Target8.74 (100.46%)
Short Float %15.47%
Short Ratio6.76
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.63%
Min EPS beat(2)0.47%
Max EPS beat(2)12.79%
EPS beat(4)4
Avg EPS beat(4)8.15%
Min EPS beat(4)0.47%
Max EPS beat(4)12.79%
EPS beat(8)6
Avg EPS beat(8)0.67%
EPS beat(12)9
Avg EPS beat(12)8.96%
EPS beat(16)12
Avg EPS beat(16)9.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.26%
PT rev (3m)-1.1%
EPS NQ rev (1m)-1.79%
EPS NQ rev (3m)17.5%
EPS NY rev (1m)-0.42%
EPS NY rev (3m)-0.69%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.95
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS0
BVpS0.73
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -53.83%
ROE -120.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.37%
ROA(5y)-41.34%
ROE(3y)-86.33%
ROE(5y)-74.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.55
Quick Ratio 4.55
Altman-Z -3.99
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)135.8%
Cap/Depr(5y)216.07%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36%
EPS Next Y22.66%
EPS Next 2Y22.71%
EPS Next 3Y13.74%
EPS Next 5Y6.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.46%
EBIT Next 3Y6.62%
EBIT Next 5YN/A
FCF growth 1Y44.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.98%
OCF growth 3YN/A
OCF growth 5YN/A

SANA BIOTECHNOLOGY INC / SANA FAQ

Can you provide the ChartMill fundamental rating for SANA BIOTECHNOLOGY INC?

ChartMill assigns a fundamental rating of 2 / 10 to SANA.


What is the valuation status of SANA BIOTECHNOLOGY INC (SANA) stock?

ChartMill assigns a valuation rating of 0 / 10 to SANA BIOTECHNOLOGY INC (SANA). This can be considered as Overvalued.


Can you provide the profitability details for SANA BIOTECHNOLOGY INC?

SANA BIOTECHNOLOGY INC (SANA) has a profitability rating of 1 / 10.


How financially healthy is SANA BIOTECHNOLOGY INC?

The financial health rating of SANA BIOTECHNOLOGY INC (SANA) is 6 / 10.